The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
Study Name on ClinicalTrials.gov (link is external) |
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients |
---|---|
Study Drug | Riociguat (Adempas, BAY63-2521) |
Type of Study Drug | CFTR Modulation |
Study Title | Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta ∆F508 Homozygous Cystic Fibrosis Patients. |
Study Phase | 2 |
Study Sponsor | Bayer |
Participating ECFS-CTN sites | Germany: Berlin UK: Belfast, London |
Age | 18 Years and older |